NEW YORK, Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating STAAR Surgical Company (NASDAQ: STAA) related to its sale to Alcon Research LLC. Under the terms of the proposed transaction, STAAR shar ...

Staar Surgical (STAA) reported $44.32 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 55.2%. EPS of -$0.07 for the same period compares to $0.33 a year ago.The reported revenue represents a surprise of +6.63% over the Zacks Consensus Estimate of $41.56 million. With the consensus EPS estimate being -$0.56, the EPS surprise was +87.5%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Staar Surgical (STAA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +87.50%. A quarter ago, it was expected that this maker of implantable lenses would post a loss of $0.59 per share when it actually produced a loss of $0.52, delivering a surprise of +11.86%.Over the last four quarters, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25510 Commercentre Drive Lake Forest, California 92630 (I.R.S. Employer Identification No.) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 27, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 STAAR Surgical Reports Second Quarter 2025 Results LAKE FOREST, CA, August 6, 2025 --- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Gross profit margin for the second quarter of 2025 was 74.0% of total net sales compared to the prior year quarter of 79.2% of total net sales and 65.8% of total net sales in the first qu ...

SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC). Background: On August 5, 2025, STAAR Surgical and Alcon entered into a definitive merger agreement. Under the terms of the agreement, holders of STAAR Surgical’s common stock will receive $28.00 in cash for e ...

Lisa Bedell Clive +44 207 676 7256 lisa.clive@bernsteinsg.com Delphine Le Louet +33 1 42 13 92 93 delphine.le-louet@bernsteinsg.com 6 June 2025 European Consumer Medical Technologies Global Ophthalmology: Laser-focused on procedure growth, mix, and China: A primer on the Refractive market Susannah Ludwig +41 582 723 127 susannah.ludwig@bernsteinsg.com Lee Hambright +1 917 344 8429 lee.hambright@bernsteinsg.com Richard Hombach +44 207 762 1858 richard.hombach@bernsteinsg.com Deeksha Pandey +1 917 344 8447 de ...

STAAR Surgical Company (STAA) FY Conference Summary Company Overview - STAAR Surgical is a 43-year-old company recognized as a global leader in ophthalmic surgery, offering a superior solution to LASIK with its EVO ICL lens technology [3][4] - The company operates in 75 countries, holding a significant refractive market share, particularly in Japan where it has a 70% share due to negative perceptions of LASIK [5][6] Core Points and Arguments - **Product Advantages**: The EVO ICL lens is reversible, provides UV protection, does not induce dry eye, and preserves corneal tissue, leading to rapid recovery and better contrast vision [4][12][14] - **Market Position**: STAAR holds approximately 12% of the global refractive market share, with significant opportunities for growth, especially in China and India [6][20] - **Growth Drivers**: The company anticipates growth driven by macroeconomic improvements and increased patient comfort with surgical options as word-of-mouth spreads [6][10][30] - **Financial Performance**: In FY 2024, STAAR reported revenues of $313.9 million, a 3% decline from FY 2023, primarily due to challenges in the Chinese market [10][34] - **Margins**: Gross margins decreased from 78.5% to 65.8% due to reduced production volume and increased reserves for obsolete inventory [35] Challenges and Strategic Focus - **Market Challenges**: The company faces headwinds from patient reluctance to pursue surgical options, particularly in the U.S., where fear of surgery is a significant barrier [6][27] - **China Market Concerns**: There are investor concerns regarding inventory levels and tariff issues in China, but the company believes these are transitory and manageable [21][41] - **Operational Restructuring**: STAAR is undergoing a restructuring to reduce SG&A expenses to a $225 million run rate, which is expected to improve financial health [36][42] Future Outlook - **Market Potential**: The myopia epidemic is expected to grow, with projections indicating that 50% of the global population may be affected by 2050, presenting a substantial market opportunity for STAAR [45] - **Long-term Confidence**: The company is optimistic about returning to historical earnings and cash flow generation as macroeconomic conditions improve [46][51] - **Strategic Shift**: There is a focus on expanding the market beyond current surgical candidates to include those using glasses and contacts, aiming to increase overall market penetration [55] Additional Insights - **Regulatory Wins**: Recent approvals in China for new product variations are seen as positive developments that could enhance market presence [17][22] - **Sales Growth**: Despite challenges, the company achieved a 9% year-over-year growth in markets outside of China, indicating resilience and potential for recovery [38] This summary encapsulates the key points discussed during the STAAR Surgical conference, highlighting the company's strengths, challenges, and strategic direction moving forward.

Summary of Star Surgical Conference Call Company Overview - **Company**: Star Surgical - **Industry**: Medical Devices, specifically focusing on Intraocular Collamer Lens (ICL) technology Key Points Share Buyback Program - Star Surgical announced a $30 million share repurchase program, which was not included in previous cash guidance [2][4] - Management believes the current stock valuation is not reflective of the company's potential, prompting the buyback decision [4][5] - The board has only authorized this single repurchase, indicating it may not become a regular part of the capital allocation strategy [6][7] Inventory and Revenue Expectations in China - The company expects to reach contractual inventory levels with Chinese distributors by June [11] - Anticipated revenue of $27.5 million from one distributor is expected in Q3, with no changes to this expectation [13] - Revenue guidance for Q2 is cautious, with expectations of minimal revenue but a gradual ramp-up anticipated [15][16] - The company is managing inventory closely with distributors to align with actual demand [18][19] Market Trends in China - Demand for ICLs in China appears to be stabilizing, with Q1 showing flat to slightly up procedural volumes compared to the previous year [22][23] - The company is optimistic about long-term growth in China, despite some softness in Q2 [24][37] - The company is not affected by military refractive demands, which are not part of their business model [26][27] Competition and Product Differentiation - Star Surgical faces competition from Ibrite's FakeCIC IOL, but the company believes its unique collagen-based material offers a significant advantage [39][40] - The market for ICLs is large, with over 1 billion people still using glasses or contacts, indicating room for growth despite competition [47] - The company is focused on understanding pricing strategies of competitors and how they will affect market dynamics [44][45] Financial Guidance and Market Outlook - Star Surgical withdrew its 2025 revenue guidance due to uncertainties, including tariff risks and macroeconomic concerns [50][51] - The management team is committed to transparency and aims to provide clearer insights into market opportunities and risks [49][52] - Long-term growth expectations remain positive, with a focus on disciplined capital allocation and market share growth [61][62] Research and Development Opportunities - The company is exploring the use of its collagen material in other therapeutic areas, particularly within ophthalmology [57][58] - R&D spending is significant, but the company aims to focus on projects that can yield meaningful results in a timely manner [58] U.S. Market Strategy - The U.S. market remains critical for Star Surgical, with a current market share in the low to mid-single digits for EVO [60][61] - The company achieved over 50% market share in Japan, indicating potential for growth in the U.S. when market conditions align [62] Additional Insights - The management acknowledges past challenges in meeting revenue expectations and aims to set more realistic future guidance [61][62] - The company is prepared for the upcoming high season in China with adequate inventory positioned for demand [34][35]

Group 1 - STAAR Surgical's shares have sharply rebounded after a selloff following Q1 earnings [1] - Management has indicated an improved demand outlook in China, although growth outside of China was only 9% in Q1 [1] Group 2 - The investment thesis focuses on identifying undercovered companies, particularly in technology, software, electronics, and energy transition sectors [1] - The analysis aims to uncover asymmetric investment opportunities to achieve market-beating returns [1]